Form 4: Arcellx Chief Medical Officer Christopher Heery Reports Stock Sales and Option Exercises

Christopher Heery, Chief Medical Officer of Arcellx, Inc., reports exercising stock options and selling shares of common stock on September 3, 2024, according to a Form 4 filing with the SEC.

Summary

• On September 3, 2024, Christopher Heery, the Chief Medical Officer of Arcellx, Inc., engaged in transactions involving the company's stock.
• Heery exercised stock options to acquire 22,000 shares at $15 and 5,451 shares at $6.28.
• Concurrently, Heery sold a total of 27,451 shares at prices ranging from $66.0471 to $70.0698, with weighted average prices reported for each block of shares sold.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 22, 2023.
• Following these transactions, Heery directly owns 9,278 shares of common stock and holds options for 135,837 shares at an exercise price of $15 and 43,604 shares at an exercise price of $6.28.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions. The sales are under a pre-arranged plan, so they don't necessarily indicate a negative outlook.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence, although the Rule 10b5-1 plan mitigates this concern.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates